cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity-Reference-Cited by-同舟云学术

cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity

Published:2020-08-12 Issue:7822 Volume:584 Page:624-629
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Ferris Stephen T.^ORCID,Durai Vivek,Wu Renee,Theisen Derek J.,Ward Jeffrey P.,Bern Michael D.,Davidson Jesse T.^ORCID,Bagadia Prachi,Liu Tiantian,Briseño Carlos G.,Li Lijin,Gillanders William E.,Wu Gregory F.,Yokoyama Wayne M.^ORCID,Murphy Theresa L.,Schreiber Robert D.,Murphy Kenneth M.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

https://www.nature.com/articles/s41586-020-2611-3.pdf

Reference50 articles.

1. Guilliams, M. et al. Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny. Nat. Rev. Immunol. 14, 571–578 (2014).

2. Hildner, K. et al. Batf3 deficiency reveals a critical role for CD8α+ dendritic cells in cytotoxic T cell immunity. Science 322, 1097–1100 (2008).

3. Cancel, J. C., Crozat, K., Dalod, M. & Mattiuz, R. Are conventional type 1 dendritic cells critical for protective antitumor immunity and how? Front. Immunol. 10, 9 (2019).

4. Dudziak, D. et al. Differential antigen processing by dendritic cell subsets in vivo. Science 315, 107–111 (2007).

5. Binnewies, M. et al. Unleashing type-2 dendritic cells to drive protective antitumor CD4+ T cell immunity. Cell 177, 556–571 (2019).

Cited by 344 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phenotypic and spatial heterogeneity of CD8+ tumour infiltrating lymphocytes;Molecular Cancer;2024-09-09

2. The renaissance of oral tolerance: merging tradition and new insights;Nature Reviews Immunology;2024-09-06

3. Dendritic cell-based immunotherapy in non-small cell lung cancer: a comprehensive critical review;Frontiers in Immunology;2024-09-06

4. In vivo dendritic cell reprogramming for cancer immunotherapy;Science;2024-09-05

5. CD4+ T cells in antitumor immunity;Trends in Cancer;2024-09